Related Experiment Videos
Moricizine-induced proarrhythmia
1Department of Clinical Cardiac Electrophysiology, Marquette General Hospital, Michigan, USA.
Abstract:
Moricizine is a Class I antiarrhythmic drug currently approved for the treatment of life-threatening ventricular arrhythmias. The drug has received significant attention because of its role in the Cardiac Arrhythmia Suppression Trial. Previous data suggested that the agent has a relatively low proarrhythmic potential. This may lead clinicians to use the drug empirically for less significant ventricular arrhythmias. We report a case of life-threatening late proarrhythmia caused by moricizine and comment on our experience with this agent. We feel that this drug has significant proarrhythmic potential and should not be used empirically to treat ventricular ectopy especially in patients with underlying structural heart disease.
Insights
Moricizine, a Class I antiarrhythmic, may cause life-threatening proarrhythmia, contrary to previous assumptions. This cardiac arrhythmia risk highlights the need for caution, especially in patients with structural heart disease.
Area of Science:
- Pharmacology
- Cardiology
Background:
- Moricizine is a Class I antiarrhythmic drug approved for life-threatening ventricular arrhythmias.
- Previous studies suggested a low proarrhythmic potential for moricizine.
- The drug was notably studied in the Cardiac Arrhythmia Suppression Trial.
Observation:
- A case of life-threatening late proarrhythmia caused by moricizine is reported.
- The authors share their clinical experience with moricizine.
Findings:
- Moricizine demonstrates a significant proarrhythmic potential.
- This potential can manifest as late-onset arrhythmias.
Implications:
- Moricizine should not be used empirically for ventricular ectopy.
- Caution is advised when prescribing moricizine, particularly in patients with underlying structural heart disease.
- Clinical use of moricizine requires careful risk-benefit assessment due to its proarrhythmic effects.